Therion Biologics ceased operations in 2006 after filing for Chapter 7 bankruptcy following clinical trials of two lead cancer drugs that did not succeed. The company previously had developed immunotherapies for the treatment of various cancers and preventive vaccines for AIDS. The company's therapeutic products aimed to harness the power of the cellular immune system to treat major cancers including colorectal, lung, prostate, breast & ovarian and melanoma. Therion also developed multi-genic vaccines for the successful prevention of AIDS. The firm had commercial rights to live, attenuated HIV vaccine technology developed at Harvard University. These multi-genic vaccines are designed to achieve the efficacy of live, attenuated AIDS vaccines with the safety of the company's recombinant pox virus products.
